AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4390958 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 8
Study 4390958 — intervention group
Group type: COMPARATOR
Intervention: Dexpropranolol
Number of subjects: 8
Study 4390958 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 31899602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 150 mg daily for 28 days
Number of subjects: 0
Study 31899602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant (100-400 mg single and multiple ascending doses)
Number of subjects: 0
Study 31899602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30737568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified protocol (1-cm-thick slabs)
Number of subjects: 894
Study 30737568 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (slabs + 1-mm-spaced planes)
Number of subjects: 894
Study 28606652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1mg/kg
Number of subjects: 488
Study 28606652 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium 1mg/kg
Number of subjects: 488
Study 26440829 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (education about the disease, diet therapy, stress reduction methods, effective cough, breathing exercises, muscle stretching exercises) practiced at home three times per week for 7 weeks.
Number of subjects: 66
Study 26440829 — intervention group
Group type: COMPARATOR
Intervention: Routine visits and weekly telephone follow-up (Control group).
Number of subjects: 66
Study 23436437 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5 mL, two times a day for 8 weeks)
Number of subjects: 70
Study 23436437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2.5 mL, two times a day for 8 weeks)
Number of subjects: 70
Study 21472722 — intervention group
Group type: EXPERIMENTAL
Intervention: mailed fecal occult blood test (FOBT) card and instructions on how to complete the test (mailed FOBT only)
Number of subjects: 501
Study 21472722 — intervention group
Group type: EXPERIMENTAL
Intervention: mailed FOBT card and instructions on how to complete the test, telephone reminders, and home visits (mailed FOBT and outreach)
Number of subjects: 501
Study 21472722 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 501
Study 21472722 — intervention group
Group type: EXPERIMENTAL
Intervention: mailed FOBT only and mailed FOBT and outreach
Number of subjects: 501
Study 19309326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 16 sessions
Number of subjects: 40
Study 19309326 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group) for 3 months
Number of subjects: 40
Study 19309326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40
Study 19309326 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 40
Study 16683383 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation radiation therapy (CFRT)
Number of subjects: 192
Study 16683383 — intervention group
Group type: COMPARATOR
Intervention: Split-course accelerated hyperfractionated schedule (S-AHF)
Number of subjects: 192
Study 16683383 — intervention group
Group type: EXPERIMENTAL
Intervention: CFRT plus concomitant chemotherapy (CT)
Number of subjects: 192
Study 15223884 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (ISO)
Number of subjects: 20
Study 15223884 — intervention group
Group type: COMPARATOR
Intervention: Isokinetic eccentric exercise (ECC)
Number of subjects: 20
Study 11421895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 80
Study 11421895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9241005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study 9241005 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 30
Study 9241005 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 30
Study 8279248 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac before surgery
Number of subjects: 64
Study 8279248 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed treatment with Diclofenac
Number of subjects: 64
Study 8279248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2897300 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol
Number of subjects: 12
Study 2897300 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 12
Study 30511433 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (IG)
Number of subjects: 39
Study 30511433 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 39
Study 29853843 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-week aerobic exercise intervention
Number of subjects: 28
Study 27276802 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic assisted single-bundle ACL reconstruction combined with internal tension-relieving technique (group A)
Number of subjects: 51
Study 27276802 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic assisted single-bundle ACL reconstruction (group B)
Number of subjects: 51
Study 24424073 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 5000 IU daily for 28 days
Number of subjects: 0
Study 24424073 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 150,000 IU cholecalciferol
Number of subjects: 0
Study 22024477 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inhalation of milrinone (Mil group)
Number of subjects: 30
Study 22024477 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 30
Study 19571633 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management using Resident Assessment Instrument-Home Care (RAI-HC)
Number of subjects: 92
Study 19571633 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention group
Number of subjects: 92
Study 17346715 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-androgen (cyproterone acetate) plus estrogen
Number of subjects: 19
Study 17346715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16353851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping therapy for sentence production
Number of subjects: 5
Study 16353851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5
Study 12241833 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 120
Study 12241833 — intervention group
Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 120
Study 12241833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 9748424 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational dietary intervention
Number of subjects: 121
Study 9748424 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary intervention
Number of subjects: 121
Study 8270443 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiation therapy plus 5-fluorouracil (5-FU)
Number of subjects: 87
Study 8270443 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiation therapy plus hycanthone (HYC)
Number of subjects: 87
Study 2913977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin with dihydroergotamine (A)
Number of subjects: 213
Study 2913977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin with dihydroergotamine (B)
Number of subjects: 213
Study 2913977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 213
Study 2913977 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 213
Study 4601222 — intervention group
Group type: COMPARATOR
Intervention: 26° ‐adapted RSV vaccine (28 children)
Number of subjects: 50
Study 4601222 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (25 children)
Number of subjects: 50
Study 4601222 — intervention group
Group type: COMPARATOR
Intervention: Temperature-sensitive mutant strain (ts-1) (22 children)
Number of subjects: 50
Study 4601222 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (21 children)
Number of subjects: 50
Study 31174514 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat (SRT) model including universal Stage 1 ASD screening, immediate referral to community-based EI program, and provision of evidence-based ASD-specialized treatment.
Number of subjects: 0
Study 31174514 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-Refer-Treat (SRT) model
Number of subjects: 0
Study 28494136 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH (technology-supported)
Number of subjects: 96
Study 28494136 — intervention group
Group type: EXPERIMENTAL
Intervention: STND (standard)
Number of subjects: 96
Study 28494136 — intervention group
Group type: COMPARATOR
Intervention: SELF (self-guided)
Number of subjects: 96
Study 26519046 — intervention group
Group type: EXPERIMENTAL
Intervention: EmotionRegulation (transdiagnostic Internet-based protocol)
Number of subjects: 200
Study 26519046 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 23531226 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity aerobic exercise program (TR, n = 10)
Number of subjects: 19
Study 23531226 — intervention group
Group type: COMPARATOR
Intervention: Non-trained group (NT, n = 9)
Number of subjects: 19
Study 23531226 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (C, n = 10)
Number of subjects: 19
Study 22754060 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV and AIDS training programme (2 days duration)
Number of subjects: 103
Study 22754060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 103
Study 19147609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4570
Study 19147609 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4570
Study 17534809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nagahara phaco‐chop maneuver (Group 2)
Number of subjects: 50
Study 17534809 — intervention group
Group type: COMPARATOR
Intervention: Divide and conquer technique (Group 1)
Number of subjects: 50
Study 15143716 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong capsule (PNS)
Number of subjects: 120
Study 15143716 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASP)
Number of subjects: 120
Study 14999615 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS type V CPS‐tetanus toxoid (TT) vaccine
Number of subjects: 35
Study 14999615 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS type V CPS‐cross‐reactive material (CRM(197)) conjugate vaccine
Number of subjects: 35
Study 14999615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10355575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 50 mg
Number of subjects: 110
Study 10355575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 10355575 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg
Number of subjects: 110
Study 10355575 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg
Number of subjects: 110
Study 10355575 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg
Number of subjects: 110
Study 10355575 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg
Number of subjects: 110
Study 8955653 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 10 mg/m2 orally
Number of subjects: 12
Study 8955653 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 10 to 25 mg/m2/d orally for 5 days with 776C85 3.7 mg/m2/d orally
Number of subjects: 12
Study 8955653 — intervention group
Group type: EXPERIMENTAL
Intervention: 776C85 3.7 mg/m2/d orally
Number of subjects: 12
Study 8955653 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU IV route
Number of subjects: 12
Study 8955653 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU oral route
Number of subjects: 12
Study 1774677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 32
Study 1774677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation plus cementation of a cast gold post
Number of subjects: 32
Study 1774677 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 32
Study 1774677 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 32
Study 7043497 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropic drug (tamitinol dihydrochloride coated tablets of 300 mg t.i.d.)
Number of subjects: 42
Study 7043497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30916527 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist joint splinting combined with physical therapy
Number of subjects: 40
Study 30916527 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 40
Study 30012193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise combined with conventional exercise of cardiac rehabilitation (CR)
Number of subjects: 120
Study 30012193 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise of cardiac rehabilitation (CR) alone
Number of subjects: 120
Study 26991616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose group (15 mg/kg TXA before surgery and saline 3 hours later)
Number of subjects: 108
Study 26991616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose group (10 mg/kg TXA before and 10 mg/kg TXA 3 hours after surgery)
Number of subjects: 108
Study 26991616 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline before and 3 hours after surgery)
Number of subjects: 108
Study 26991616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose group
Number of subjects: 108
Study 26991616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose group
Number of subjects: 108
Study 26991616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 24289892 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (40mg/day)
Number of subjects: 40
Study 24289892 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (30mg/day)
Number of subjects: 40
Study 21604039 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic implant removal
Number of subjects: 29
Study 21604039 — intervention group
Group type: COMPARATOR
Intervention: Open implant removal
Number of subjects: 29
Study 20605097 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized treadmill walking at 5 speeds
Number of subjects: 17
Study 20605097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-correlated surrogates
Number of subjects: 17
Study 20605097 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional ARMA process
Number of subjects: 17
Study 18019592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (James Cycle Protocol)
Number of subjects: 216
Study 16282842 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 66
Study 16282842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12168782 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Number of subjects: 46
Study 12168782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10080416 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour continuous electrocardiographic monitoring (VCG)
Number of subjects: 308
Study 10080416 — intervention group
Group type: COMPARATOR
Intervention: Admission ECG
Number of subjects: 308
Study 10080416 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST depression with VCG monitoring
Number of subjects: 308
Study 7675364 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐labelled 15‐(p‐iodo‐phenyl)‐3,R,S‐methylpentadecanoic acid (BMIPP)
Number of subjects: 15
Study 7675364 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐meta‐iodobenzyl guanidine (MIBG)
Number of subjects: 15
Study 7675364 — intervention group
Group type: COMPARATOR
Intervention: 201Tl/99Tcm‐pyrophosphate (Tl‐PYP)
Number of subjects: 15
Study 7675364 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed MIBG
Number of subjects: 15
Study 31074178 — intervention group
Group type: COMPARATOR
Intervention: Anamorelin 5 mg
Number of subjects: 25
Study 31074178 — intervention group
Group type: COMPARATOR
Intervention: Anamorelin 25 mg
Number of subjects: 25
Study 31074178 — intervention group
Group type: COMPARATOR
Intervention: Anamorelin 25 mg and 50 mg
Number of subjects: 25
Study 28403895 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 150
Study 28403895 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 150
Study 28403895 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 26742380 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial anti-fogging solution (Ultrastop®)
Number of subjects: 71
Study 26742380 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby shampoo solution (Johnson's® no more tear®)
Number of subjects: 71
Study 26742380 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 71
Study 23002172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 121
Study 23002172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Appliances (OAs)
Number of subjects: 121
Study 21219381 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (EPA and DHA), 1.84 g per day for 32 weeks
Number of subjects: 238
Study 19633072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MetS
Number of subjects: 539
Study 19633072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MetS with insulin resistance (IR)
Number of subjects: 539
Study 19633072 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without MetS)
Number of subjects: 539
Study 16719596 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with CHD symptoms under stress
Number of subjects: 0
Study 16719596 — intervention group
Group type: COMPARATOR
Intervention: Female patients with CHD symptoms without stress
Number of subjects: 0
Study 16719596 — intervention group
Group type: COMPARATOR
Intervention: Male patients with CHD symptoms under stress
Number of subjects: 0
Study 16719596 — intervention group
Group type: COMPARATOR
Intervention: Male patients with CHD symptoms without stress
Number of subjects: 0
Study 14985485 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab maintenance therapy (5 mg/kg every 8 weeks)
Number of subjects: 306
Study 14985485 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance
Number of subjects: 306
Study 11527647 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with harmonic imaging and contrast injection
Number of subjects: 58
Study 11527647 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography without contrast injection
Number of subjects: 58
Study 11527647 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with contrast injection
Number of subjects: 58
Study 9481960 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen
Number of subjects: 30
Study 9481960 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg acetaminophen with 10 mg hydrocodone
Number of subjects: 30
Study 9481960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9481960 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ketoprofen
Number of subjects: 30
Study 8243705 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8
Study 8243705 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study 3105913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 1.75 mg/kg given over 12 hr (0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr)
Number of subjects: 24
Study 3105913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3105913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human tissue-type plasminogen activator (rt-PA)
Number of subjects: 24
Study 31077582 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11 (up to 100 mg/kg, p.o.)
Number of subjects: 70
Study 31077582 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11 (up to 100 mg/kg daily for seven days, orally)
Number of subjects: 70
Study 31077582 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11 (multiple ascending doses)
Number of subjects: 70
Study 31077582 — intervention group
Group type: EXPERIMENTAL
Intervention: BT-11 (0.01 µM ex vivo treatment)
Number of subjects: 70
Study 31077582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30915987 — intervention group
Group type: EXPERIMENTAL
Intervention: PNK (paracetamol, nefopam, ketoprofen)
Number of subjects: 237
Study 30915987 — intervention group
Group type: COMPARATOR
Intervention: C (control with saline as placebo)
Number of subjects: 237
Study 30915987 — intervention group
Group type: COMPARATOR
Intervention: N (nefopam)
Number of subjects: 237
Study 28214613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized skin care regimens (body wash and twice daily applications of leave-on products for eight weeks)
Number of subjects: 133
Study 28214613 — intervention group
Group type: COMPARATOR
Intervention: Routine skin care (control group)
Number of subjects: 133
Study 25954107 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo biopsy forceps (Radial Jaw 4 jumbo)
Number of subjects: 37
Study 23470803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DRI (300 mg per day)
Number of subjects: 30
Study 23470803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (standard dose DRI 150 mg + hydrochlorothiazide 12.5 mg)
Number of subjects: 30
Study 23470803 — intervention group
Group type: COMPARATOR
Intervention: Standard dose DRI (150 mg)
Number of subjects: 30
Study 20957659 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly for 10 years
Number of subjects: 1272